Troriluzole (DB15079): A Comprehensive Monograph on a Novel Glutamate Modulator from Prodrug Design to Clinical Application

Executive Summary

Troriluzole (DB15079) is an investigational small molecule therapeutic representing a sophisticated application of prodrug chemistry. It is a third-generation tripeptide prodrug of riluzole, a medication approved for amyotrophic lateral sclerosis.[1] The primary rationale for its development was to engineer a molecule that retains the glutamate-modulating activity of riluzole while systematically overcoming the parent compound's significant clinical liabilities, which include poor and variable bioavailability, a negative food effect, and dose-dependent hepatotoxicity.[4]

The principal mechanism of action of Troriluzole, mediated through its active metabolite riluzole, is the normalization of synaptic glutamate levels. This is achieved through a dual action: enhancing the uptake and clearance of glutamate from the synapse by augmenting the function of glial excitatory amino acid transporters (EAATs) and inhibiting the presynaptic release of glutamate.[7] This central mechanism is complemented by ancillary actions, including the inactivation of voltage-dependent sodium channels.[10]

The clinical development program for Troriluzole has been extensive and marked by both significant setbacks and strategic successes. The drug has been investigated across a range of central nervous system disorders, including Spinocerebellar Ataxia (SCA), Alzheimer's Disease (AD), Obsessive-Compulsive Disorder (OCD), and Generalized Anxiety Disorder (GAD), as well as in oncology.[2] Development for OCD was terminated following failures in Phase 3 trials, and a pivotal Phase 2/3 study in mild-to-moderate AD did not meet its primary endpoints.[14] In contrast, the SCA program, despite an initial pivotal trial failing to meet its primary endpoint, yielded promising results in a genetically defined subgroup (SCA3) and demonstrated a significant reduction in patient falls. These findings, bolstered by a positive long-term real-world evidence study, form the basis of a New Drug Application (NDA) currently under Priority Review by the U.S. Food and Drug Administration (FDA).[16]

Pharmacokinetic studies have confirmed the success of the prodrug design. Compared to riluzole, Troriluzole administration results in higher bioavailability, permits once-daily dosing, eliminates the negative food effect, and crucially, demonstrates a markedly improved hepatic safety profile, with a substantially lower incidence of clinically significant liver enzyme elevations.[6] This favorable safety profile is a key differentiator.

The regulatory journey of Troriluzole is complex; while the NDA for SCA is advancing with the FDA, a Marketing Authorisation Application was withdrawn from the European Medicines Agency (EMA) following unresolved questions regarding its status as a new active substance and its efficacy.[21] If approved in the U.S., Troriluzole would become the first-in-class therapy for SCA, addressing a profound unmet medical need for this debilitating rare disease.

Drug Profile and Chemical Characteristics

This section provides a comprehensive catalog of Troriluzole's nomenclature, structural details, and physicochemical properties, establishing a definitive molecular identity for the compound.

Nomenclature and Identifiers

Troriluzole has been identified by a variety of names and codes throughout its development and in scientific literature.

• Generic Names: The officially recognized names are Troriluzole (United States Adopted Name, USAN) and troriluzole (International Nonproprietary Name, INN).[23]
• Synonyms and Code Names: The compound is widely known by its primary development code, BHV-4157. Other synonyms and codes include Trigriluzole, BHV-4157a, BHV 4157, FC-4157, and the latinized form troriluzolum.[1]
• Systematic (IUPAC) Name: The formal chemical name according to IUPAC nomenclature is 2-amino-N-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide.[11]
• Chemical Identifiers: Standardized identifiers from major chemical and drug databases are listed in Table 1. These include its CAS (Chemical Abstracts Service) Registry Number, 1926203-09-9, and its DrugBank accession number, DB15079.[11]
• Salt Form: A hydrochloride salt form, Troriluzole hydrochloride, has also been used in development and is identified by CAS number 1926204-76-3 and UNII code BQ5F77DZS3.[30]

Chemical Structure and Physicochemical Properties

Troriluzole is a synthetic organic molecule, specifically a tripeptide conjugate of the benzothiazole derivative riluzole.

• Molecular Formula: C15​H16​F3​N5​O4​S.[1]
• Molecular Weight: The average molecular weight is 419.38 g·mol⁻¹.[1]
• Monoisotopic Mass: The precise monoisotopic mass is 419.08750967 Da.[23]
• Structural Representations: The molecule's structure is defined by the following standard notations:
• SMILES: CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN.[2]
• InChI: InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17,18)/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25).[11]
• InChIKey: YBZSGIWIPOUSHY-UHFFFAOYSA-N.[11]
• Computed Physicochemical Properties: Key molecular properties that predict its pharmacokinetic behavior are summarized in Table 1. The molecule's relatively low LogP values and high polar surface area are consistent with a compound designed for oral administration that interacts with biological transporters. It fully conforms to Lipinski's Rule of Five, predicting favorable absorption and permeation characteristics.[26]

Classification

Troriluzole is classified based on its chemical structure, therapeutic action, and regulatory coding.

• Chemical Class: It is a benzothiazole derivative, characterized by the core riluzole structure, and is further classified as a tripeptide conjugate.[1]
• Pharmacological Class: Its primary classification is as a glutamate modulator and a neuroprotective agent.[2]
• Anatomical Therapeutic Chemical (ATC) Code: The World Health Organization has assigned Troriluzole the ATC code N07XX23, placing it in the category of "Other nervous system drugs".[11]
• Developmental Status: Troriluzole is an investigational drug that has reached Phase 3 in clinical development across multiple indications.[23]

Table 1: Key Identifiers and Physicochemical Properties of Troriluzole

Property	Value
Common Name	Troriluzole
Synonyms	Trigriluzole, BHV-4157, FC-4157
DrugBank ID	DB15079
CAS Number	1926203-09-9
Molecular Formula	C15​H16​F3​N5​O4​S
Molecular Weight	419.38 g·mol⁻¹
SMILES	CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN
ATC Code	N07XX23
LogP	-0.27 to 0.67
TPSA	126.65 Ų to 154.89 Ų
Lipinski's Rule of Five	0 violations

Pharmacology and Mechanism of Action

The pharmacology of Troriluzole is fundamentally linked to its identity as a prodrug of riluzole. Its design represents a direct and rational chemical engineering solution to the known clinical deficiencies of its parent compound. This section details the rationale for its creation, its bioactivation, and its multi-modal mechanism of action that has prompted its investigation across a wide spectrum of diseases.

Prodrug Rationale and Bioactivation

The development of Troriluzole was not an exploratory effort but a targeted strategy to create a superior version of riluzole. Riluzole, while effective in modulating glutamate, is hampered by a problematic clinical pharmacology profile that has limited its broader therapeutic application. These deficiencies include poor and highly variable oral bioavailability of approximately 60%, a significant negative food effect that can reduce peak blood levels by 45%, and the need for twice-daily dosing on an empty stomach to ensure adequate exposure.[4] The primary cause of these issues is extensive and variable first-pass metabolism in the liver, mediated predominantly by the cytochrome P450 isoform CYP1A2.[3] This process not only reduces systemic drug levels but also contributes to a dose-dependent risk of hepatotoxicity, a significant safety concern.[5]

To circumvent these limitations, Troriluzole was rationally designed as a third-generation tripeptide prodrug.[2] The structure consists of the active riluzole moiety conjugated to a tripeptide carrier (H-Gly-Gly-Sar-OH).[1] This modification serves two critical functions. First, the tripeptide structure is recognized by and actively absorbed in the gastrointestinal tract via the high-capacity peptide transporter 1 (PepT1), enhancing its uptake.[1] Second, the conjugation masks the exocyclic nitrogen of riluzole, preventing its recognition as a substrate by CYP1A2 during its first pass through the liver.[3]

Following absorption into the bloodstream, the prodrug is rapidly cleaved by ubiquitous plasma aminopeptidases, which hydrolyze the peptide bonds and release the active riluzole moiety into systemic circulation.[1] This bioactivation pathway successfully bypasses the problematic first-pass hepatic metabolism, thereby solving the core issues of low bioavailability and high initial liver burden that plague the parent drug.[5]

Primary Mechanism of Action: Glutamate Modulation

The therapeutic activity of Troriluzole is mediated by its active metabolite, riluzole, which functions as a glutamate modulating agent to normalize synaptic glutamate levels.[2] This mechanism is highly relevant to a range of neurological and psychiatric disorders where glutamatergic dysregulation and subsequent excitotoxicity are implicated as key pathophysiological drivers, including SCA, AD, and OCD.[8] The normalization of glutamate homeostasis is achieved through a dual action on both glutamate clearance and release.

1. Enhanced Glutamate Clearance: Troriluzole augments the expression and function of excitatory amino acid transporters (EAATs), specifically EAAT1 (GLAST) and EAAT2 (GLT-1). These transporters are located on the surface of glial cells, particularly astrocytes, and are responsible for the rapid removal of excess glutamate from the synaptic cleft, thereby terminating the excitatory signal and preventing excitotoxic damage.[1]
2. Inhibition of Glutamate Release: The drug also acts presynaptically to inhibit the release of glutamate from nerve terminals. This effect is thought to be mediated primarily through the inactivation of voltage-dependent sodium channels on the presynaptic membrane, which reduces neuronal excitability and depolarization-dependent neurotransmitter release.[1]

Secondary and Ancillary Mechanisms (Inherited from Riluzole)

In addition to its primary effects on glutamate homeostasis, Troriluzole inherits a suite of other pharmacological actions from riluzole, contributing to its pleiotropic profile. This multi-modal mechanism helps explain the rationale for its investigation across a broad and diverse range of diseases.

• Inactivation of Voltage-Dependent Sodium Channels: Riluzole preferentially blocks tetrodotoxin (TTX)-sensitive voltage-dependent sodium channels, which are often upregulated or hyperexcitable in damaged neurons. This action contributes to its neuroprotective and anticonvulsant properties by stabilizing neuronal membranes.[1]
• Postsynaptic Receptor Modulation: Evidence suggests that riluzole can also act at the postsynaptic level. It has been shown to be a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors and a direct inhibitor of kainate receptors, two key subtypes of ionotropic glutamate receptors.[41]
• Interference with Intracellular Signaling: Riluzole appears to interfere with intracellular signaling cascades that are initiated following glutamate receptor binding, potentially involving G-protein-dependent pathways.[23]
• Other Targets: Other reported actions include the activation of certain calcium-activated potassium channels and the allosteric potentiation of inhibitory GABA-A receptors, which would further contribute to a reduction in overall neuronal excitability.[35]

Pharmacodynamic Effects in Disease Models

The multifaceted mechanism of Troriluzole and riluzole translates into observable pharmacodynamic effects in various preclinical and clinical models.

• Neuroprotection: The drug demonstrates clear neuroprotective effects in vitro and in vivo, shielding neurons from anoxic damage and glutamate-induced excitotoxicity.[1] A 2024 study in a mouse model of Alzheimer's disease reported that Troriluzole could reverse early pathological changes, reduce harmful glutamate levels, and improve synaptic and memory function.[11]
• Oncology: The rationale for its use in cancer stems from the role of glutamate signaling in promoting tumor growth and metastasis. By functionally inhibiting the metabotropic glutamate receptor 1 (mGluR1) via reduced glutamate availability, Troriluzole has the potential to downregulate pro-survival pathways such as MAPK and PI3K/AKT.[52]
• Neuro-oncology: In glioblastoma, where tumor cells can form synaptic connections with neurons and hijack glutamatergic signals for growth, Troriluzole is being investigated for its ability to disrupt this neuro-tumoral communication. A primary objective of an early phase trial is to measure the reduction in high-gamma band power, a neurophysiological marker of cortical hyperexcitability, in the tissue surrounding recurrent glioblastoma tumors.[54]

Clinical Pharmacokinetics and Metabolism

The clinical pharmacokinetic profile of Troriluzole is central to its value proposition. Studies have quantitatively demonstrated that the prodrug design successfully achieved its primary objectives of enhancing the delivery and improving the clinical handling of the active moiety, riluzole.

Absorption and Bioavailability

Following oral administration, Troriluzole is rapidly absorbed and efficiently converted to riluzole.

• Conversion and Tmax: The conversion is so rapid that plasma concentrations of the parent prodrug, Troriluzole, are low and transient.[4] After a 280 mg oral dose of Troriluzole, the peak plasma concentration (Cmax) of Troriluzole itself was only 5.4 ng/mL, whereas the resulting Cmax of the active riluzole metabolite was nearly 100-fold higher at 510.4 ng/mL.[37] The time to reach this peak concentration (Tmax) for riluzole is consistently observed at approximately 2 to 3 hours post-dose.[4]
• Food Effect: A critical advantage of the Troriluzole formulation is the elimination of the negative food effect that limits riluzole. Population pharmacokinetic modeling demonstrated that administration with food or in the evening resulted in a negligible change (≤10%) in total drug exposure (AUC), confirming that Troriluzole can be taken without regard to meals.[5]
• Bioavailability: The prodrug strategy successfully enhances the systemic delivery of riluzole. Pharmacokinetic modeling showed that administration of Troriluzole resulted in a 53.8% higher relative bioavailability of riluzole compared to the administration of an equivalent dose of riluzole itself.[19] This significant increase is a direct consequence of bypassing the extensive first-pass hepatic metabolism.

Distribution, Metabolism, and Excretion

Once riluzole is released into the circulation, its disposition follows a well-characterized path.

• Distribution: Riluzole is highly protein-bound (96%), primarily to plasma albumin and lipoproteins.[36]
• Metabolism: The metabolism of riluzole is predominantly hepatic. The primary pathway involves hydroxylation by cytochrome P450 1A2 (CYP1A2) to form N-hydroxyriluzole, which is subsequently conjugated via glucuronidation for excretion.[35]
• Elimination Half-life: The elimination half-life (T½) of riluzole following Troriluzole administration is approximately 9 to 12 hours.[4]
• Steady State and Accumulation: With once-daily dosing of Troriluzole, riluzole reaches steady-state plasma concentrations by the fifth day. There is no evidence of clinically significant accumulation with long-term administration.[4]
• Dose Proportionality: The exposure to riluzole (both AUC and Cmax) increases proportionally with increasing doses of Troriluzole, indicating linear pharmacokinetics over the clinically tested range.[4]

Pharmacokinetic Variability and Drug Interactions

A key achievement of the Troriluzole program was the reduction of the high inter-patient variability that complicates the use of riluzole.

• Reduced Variability: Troriluzole administration leads to a more consistent and predictable pharmacokinetic profile. Population modeling revealed an approximately 50% reduction in the interindividual variability of both riluzole bioavailability (F) and its absorption rate constant (Ka) when compared to direct riluzole administration.[19] The coefficient of variation (CV) for riluzole Cmax following repeated Troriluzole dosing was measured at 31.6% to 41.2%, a marked improvement over the 70% variability reported for standard riluzole tablets.[4]
• Drug Interactions: Because the active metabolite riluzole is a substrate of CYP1A2, Troriluzole carries the same potential for drug-drug interactions. Co-administration with strong CYP1A2 inhibitors, such as fluvoxamine, significantly decreases riluzole clearance (by 55.6%) and increases exposure, while strong inducers would be expected to decrease exposure.[19] Consequently, the use of such agents is contraindicated.[54]
• Effect of Hepatic Impairment: A dedicated study in subjects with moderate hepatic impairment found that a single 100 mg dose of Troriluzole was well tolerated. While total riluzole exposure was not significantly altered, the concentration of unbound (pharmacologically active) riluzole was modestly increased (1.7-fold for AUC and 1.4-fold for Cmax). This increase did not cross the 2-fold regulatory threshold that would automatically necessitate a dose adjustment, suggesting a more favorable profile in hepatic impairment compared to riluzole itself.[55]

Table 2: Comparative Pharmacokinetic Profile: Riluzole vs. Troriluzole-Derived Riluzole

Parameter	Standard Riluzole Formulation	Troriluzole Formulation (as Riluzole)	Advantage of Troriluzole
Dosing Frequency	Twice-daily 5	Once-daily 4	Improved patient convenience and adherence.
Food Effect	Significant negative effect (must be taken fasting) 5	No significant food effect 5	Dosing flexibility and elimination of complex dietary restrictions.
Relative Bioavailability	Baseline ~60% (absolute) 36	53.8% higher than riluzole administration 19	More efficient and complete drug delivery to systemic circulation.
Interindividual PK Variability	High (Cmax CV ~70%) 37	Lower (Cmax CV ~31-41%) 4	More predictable and consistent drug exposure across patients.
Primary Metabolism	Extensive first-pass hepatic metabolism (CYP1A2) 5	Bypasses first-pass; cleaved in plasma 1	Reduced initial metabolic burden on the liver, contributing to improved safety.

Clinical Development and Efficacy Analysis

The clinical development of Troriluzole has been a broad and ambitious undertaking, spanning multiple high-need indications in neurology, psychiatry, and oncology. The program's trajectory provides a compelling narrative of the challenges inherent in CNS drug development, characterized by definitive failures in major indications but also by a remarkable strategic pivot that has positioned the drug for potential approval in a rare disease.

Table 3: Summary of Major Clinical Trials for Troriluzole by Indication

Indication	Trial Identifier	Phase	Key Design Feature	Primary Endpoint(s)	Outcome/Status
Spinocerebellar Ataxia (SCA)	NCT03701399	3	Randomized, placebo-controlled, 48 weeks	Change in f-SARA score	Failed to meet primary endpoint; positive post-hoc in SCA3 subgroup & fall reduction
Spinocerebellar Ataxia (SCA)	NCT06529146	3 (RWE)	Open-label vs. matched natural history cohort, 3 years	Change in f-SARA score	Met primary endpoint; demonstrated significant slowing of disease progression
Alzheimer's Disease (AD)	NCT03605667	2/3	Randomized, placebo-controlled, 48 weeks	Change in ADAS-Cog & CDR-SB	Failed to meet co-primary endpoints; development not pursued
Obsessive-Compulsive Disorder (OCD)	NCT04641143 (Pivotal)	3	Randomized, placebo-controlled, adjunctive therapy	Change in Y-BOCS score	Failed to meet primary endpoint; program terminated
Advanced Solid Tumors	NCT03229278	1b	Dose-escalation, combination with nivolumab	Safety, MTD	MTD determined; combination was safe with limited objective responses

Spinocerebellar Ataxia (SCA)

The SCA program exemplifies a modern, adaptive approach to rare disease drug development. SCA represents a group of devastating, inherited neurodegenerative disorders characterized by progressive loss of motor control for which there are no FDA-approved disease-modifying therapies, constituting a profound unmet medical need.[8]

The initial Phase 2b/3 trial (NCT02960893) failed to show a separation from placebo on its primary endpoint, the Scale for the Assessment and Rating of Ataxia (SARA), after just 8 weeks of treatment.[1] This early result highlighted the difficulty of demonstrating efficacy over short durations in a slowly progressing disease. However, data from a 48-week open-label extension of this study provided the first signal of potential long-term benefit when compared against an external natural history cohort.[1]

This signal prompted the pivotal Phase 3 trial, NCT03701399, a large-scale, 48-week, placebo-controlled study in 218 patients with various SCA genotypes.[49] The trial ultimately failed to meet its primary endpoint of change from baseline on the modified Functional SARA (f-SARA) scale in the overall study population (p=0.76).[16] This failure was attributed in part to the unexpectedly slow rate of disease progression observed in the placebo group over the 1-year period, which diminished the statistical power to detect a treatment effect.[16]

Rather than terminating the program, the sponsor conducted a rigorous post-hoc analysis that revealed two critical findings. First, in the large subgroup of patients with SCA type 3 (SCA3), the most common genotype, there was a clinically meaningful and near-significant numerical improvement with Troriluzole versus placebo (LS mean change difference -0.55, nominal p=0.053).[16] Second, across all genotypes, Troriluzole treatment was associated with a statistically significant 58% reduction in the incidence of patient-reported falls, a highly relevant and debilitating complication of the disease (nominal p=0.043).[16]

These findings provided the rationale for a strategic pivot. The sponsor designed a new study, NCT06529146, which leveraged long-term data from the open-label extension of NCT03701399 and compared it to a meticulously matched, untreated natural history cohort over a 3-year period. This real-world evidence (RWE) study yielded unequivocally positive results. It met its primary endpoint, demonstrating that Troriluzole produced a statistically significant 50-70% slowing of disease progression as measured by the f-SARA scale. The treatment benefit was sustained over the 3-year period and consistent across nine consecutive primary and secondary endpoints.[8] This robust, long-term data package now forms the cornerstone of the NDA submitted to the FDA.

Alzheimer's Disease (AD)

The investigation of Troriluzole in AD was predicated on the glutamate excitotoxicity hypothesis, which posits that excessive glutamatergic signaling contributes to the synaptic dysfunction and neuronal death seen in the disease.[40] The Phase 2/3 T2 Protect AD trial (NCT03605667) was designed to test this hypothesis in approximately 350 individuals with mild-to-moderate AD.[14]

The trial evaluated a 280 mg daily dose of Troriluzole against placebo over 48 weeks, with co-primary endpoints assessing cognition (ADAS-Cog) and global function (CDR-SB).[14] Topline results announced in January 2021 revealed that the study failed to meet both of its co-primary endpoints. No statistically significant difference was observed between the Troriluzole and placebo groups in the overall study population.[14]

A pre-specified subgroup analysis of patients with only mild AD (n=97) suggested a potential, albeit non-significant, signal. In this subgroup, there was a numerical trend favoring Troriluzole on the ADAS-Cog and on a secondary imaging endpoint of hippocampal volume loss. At 48 weeks, the mean hippocampal volume reduction was -1.1% in the Troriluzole group versus -1.6% in the placebo group (p=0.2).[14] While this observation hinted that the drug might have a disease-modifying effect in the earliest stages of the disease, the overall failure in the broad population led to the discontinuation of development for this indication.[14] This outcome suggests that by the time AD is clinically manifest, particularly in the moderate stage, the pathological cascade may be too advanced for a glutamate modulator alone to confer a significant clinical benefit, or that glutamate dysregulation is a secondary component of a more complex pathology dominated by amyloid and tau.

Obsessive-Compulsive Disorder (OCD)

The rationale for testing Troriluzole in OCD was strong, based on a growing body of evidence implicating glutamatergic hyperactivity in the cortico-striato-thalamo-cortical (CSTC) circuits that are dysfunctional in the disorder.[9] This offered a novel therapeutic target beyond the standard-of-care serotonergic agents, to which many patients have an inadequate response.[71]

An initial Phase 2/3 proof-of-concept study (NCT03299166) evaluated Troriluzole as an adjunctive therapy.[13] While the study narrowly missed its primary endpoint—change in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at 12 weeks (p=0.220)—it showed a consistent numerical improvement over placebo at all timepoints and achieved statistical significance at an earlier timepoint (Week 8, p=0.041). The treatment effect was more pronounced in patients with more severe baseline symptoms.[9]

Based on this promising signal, Biohaven advanced Troriluzole into a definitive, large-scale pivotal Phase 3 program, consisting of two identical, well-powered trials (e.g., NCT04641143) using a higher 280 mg dose.[2] However, in August 2025, the company announced that the first of these trials had failed to meet its primary endpoint.[15] Following this definitive negative result, Biohaven terminated the development of Troriluzole for OCD to reallocate resources.[15]

Oncology (Glioblastoma, Melanoma)

The exploration of Troriluzole in oncology is based on the discovery that glutamate signaling can promote tumor growth, angiogenesis, and invasion in various cancers, including melanoma and glioblastoma.[50] Previous trials with riluzole had shown biological activity but were limited by its poor pharmacokinetics. Troriluzole's optimized profile presented an opportunity to re-test this hypothesis more effectively.

A Phase 1b dose-escalation study (NCT03229278) evaluated Troriluzole in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumors. The study established a maximum tolerated dose (MTD) of 420 mg daily and found the combination to be safe. While objective responses were rare (one partial response, 7%), the trial noted that a number of patients with PD-1 resistant tumors achieved disease stabilization, suggesting potential utility.[52]

Clinical investigation is ongoing in glioblastoma (GBM), a brain tumor known to be highly dependent on neuronal glutamate for proliferation. Early-phase trials (e.g., NCT03970447, NCT06552260) are currently evaluating Troriluzole's ability to disrupt this glutamatergic signaling and slow tumor growth.[2]

Integrated Safety and Tolerability Profile

A comprehensive assessment of safety data aggregated across the entire clinical development program reveals that Troriluzole is generally well-tolerated and, most importantly, confirms that the prodrug design successfully mitigated the signature hepatotoxicity of its parent compound, riluzole.

Overall Safety Profile

Troriluzole has been administered to thousands of participants across multiple clinical trials, establishing a robust safety database.

• General Tolerability: In studies spanning diverse patient populations and indications, Troriluzole has been consistently described as well-tolerated at therapeutic doses of 140-280 mg once daily.[1] Phase 1 single ascending dose studies explored doses as high as 840 mg without identifying a maximum tolerated dose, and the incidence of adverse events did not appear to increase with dose escalation within this range.[4]
• Common Adverse Events: The most frequently reported treatment-emergent adverse events in early-phase studies in healthy volunteers were mild and transient in nature, with headache and somnolence being the most common.[4] In a Phase 1b oncology trial where Troriluzole was administered at higher doses in combination with nivolumab, the most common treatment-related adverse events were transaminitis (elevated liver enzymes) and increased lipase.[52]
• Discontinuation Rates: The rate of discontinuation due to adverse events has been consistently low across trials. For example, in a Phase 3 trial for Generalized Anxiety Disorder, the discontinuation rate for Troriluzole was 4.0%, comparable to the placebo rate of 4.5%.[1]

Hepatic Safety: The Key Differentiator

The most significant achievement of the Troriluzole program from a safety perspective is the marked improvement in its hepatic profile compared to riluzole. This was a primary objective of the prodrug design, stemming from the need to overcome the dose-dependent liver enzyme elevations that limit the use of riluzole, where approximately 8% of patients experience alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal (>3x ULN).[6]

A large, integrated analysis of pooled safety data from 1,386 participants in Phase 2/3 trials for SCA, OCD, GAD, and AD provided definitive evidence of Troriluzole's superior hepatic safety.[6] The key findings were:

• Incidence of ALT Elevations:
• ALT >3x ULN: Occurred in only 2.6% of patients treated with Troriluzole.
• ALT >5x ULN: Occurred in only 0.6% of patients.
• Comparative Risk: These rates represent an approximate three-fold reduction in the incidence of clinically significant transaminase elevations compared to the historical rates reported for riluzole (8% for >3x ULN and 2% for >5x ULN).[6]
• Clinical Course and Severity: The liver enzyme increases that were observed with Troriluzole typically occurred within the first 12 weeks of treatment and were transient, often resolving with continued treatment or upon discontinuation. Critically, across this large safety database, there were no reported cases of severe drug-induced liver injury (DILI) or any instances that met the criteria for Hy's Law, a strong indicator of a drug's potential to cause fatal liver damage.[6]

This robust dataset confirms that by bypassing first-pass hepatic metabolism, Troriluzole successfully reduces the metabolic burden on the liver and offers a significantly improved safety profile, a crucial advantage for a drug intended for chronic use in neurodegenerative diseases.

Safety in Combination Therapy

In the Phase 1b oncology study (NCT03229278), the combination of Troriluzole with the immune checkpoint inhibitor nivolumab was found to be safe and tolerable. Dose-limiting toxicities were observed at higher doses and included Grade 3 anorexia, fatigue, and atrial fibrillation, but no subjects discontinued treatment due to adverse events.[53]

Regulatory Landscape and Future Outlook

The regulatory journey of Troriluzole has been complex and divergent, providing a salient case study in the evolving standards for drug approval in rare diseases. While the path forward in the United States for the treatment of Spinocerebellar Ataxia appears promising, the application has been withdrawn in Europe, highlighting differing regulatory philosophies regarding the interpretation of complex clinical data.

U.S. Food and Drug Administration (FDA)

The NDA for Troriluzole for the treatment of SCA is currently under review by the FDA.[8] The submission and its subsequent review have been characterized by several key developments:

• Regulatory Designations: Recognizing the high unmet need in SCA, the FDA has granted Troriluzole multiple designations intended to facilitate and expedite its development and review. These include Fast Track Designation, Orphan Drug Designation (ODD), and, most significantly, Priority Review.[8] A Priority Review designation is reserved for drugs that, if approved, would offer a significant improvement in the treatment, diagnosis, or prevention of a serious condition, and it shortens the target review timeline.
• Review Timeline and PDUFA Date: The FDA accepted the NDA for review, but later extended the Prescription Drug User Fee Act (PDUFA) target action date by three months, to the fourth quarter of 2025. This extension was to allow the agency sufficient time to conduct a full review of additional data submitted by the sponsor in response to information requests.[8]
• Advisory Committee Meeting: The FDA initially informed the sponsor that it was planning to convene an advisory committee (AdCom) meeting to discuss the application—a common step for drugs with complex data packages or first-in-class mechanisms. However, in a subsequent and highly favorable development, the agency determined that an AdCom meeting was "no longer needed for regulatory decision making".[78] This is often interpreted as a positive signal, suggesting that the FDA's internal review divisions may have reached a consensus and do not require external expert consultation to proceed.
• Basis for Submission: The regulatory submission is not based on a single, successful pivotal trial. Instead, it relies on the totality of the evidence, which includes the supportive post-hoc analyses of the SCA3 subgroup and the significant reduction in falls from the initial Phase 3 trial (NCT03701399), combined with the robust, positive long-term efficacy data from the 3-year real-world evidence (RWE) study (NCT06529146).[18]

European Medicines Agency (EMA)

In stark contrast to the progress with the FDA, the Marketing Authorisation Application (MAA) for Troriluzole (under the proposed trade name Dazluma) was formally withdrawn from the EMA on March 24, 2025.[21] The withdrawal followed the identification of "unresolved issues" by the EMA's Committee for Medicinal Products for Human Use (CHMP). The primary concerns raised by the committee were:

1. Status as a New Active Substance: The CHMP expressed doubts about whether there was sufficient evidence to classify Troriluzole as a new active substance with distinct clinical benefits over its already-approved active metabolite, riluzole.[22]
2. Efficacy Data: The committee appeared to place greater weight on the failure of the primary pivotal trial (NCT03701399) to meet its pre-specified primary endpoint. The supportive post-hoc and RWE data were seemingly not considered sufficient to overcome this initial negative result.[21]

Expert Analysis and Future Perspective

The divergent paths taken by the FDA and the EMA reflect a potential schism in regulatory approaches to drug approval, particularly for rare diseases with high unmet need and challenging clinical development pathways. The FDA's actions suggest a more flexible, holistic review process that considers the "totality of the evidence," including clinically meaningful secondary endpoints (fall reduction), robust RWE, a strong safety profile, and the absence of any alternative treatments. The EMA's position, conversely, appears to reflect a more rigid adherence to the traditional hierarchy of evidence, where the failure of a pre-specified primary endpoint in a single pivotal randomized controlled trial is difficult to overcome. This case may become a significant precedent for how RWE is utilized in global regulatory submissions for rare diseases.

Given the FDA's granting of Priority Review and the subsequent cancellation of the AdCom meeting, the probability of approval for Troriluzole for SCA in the U.S. appears high. An approval would represent a landmark achievement, providing the first-ever disease-modifying therapy for the SCA patient community.

While development in AD and OCD has ceased, the successful engineering of Troriluzole as a safer and more effective delivery vehicle for riluzole means it remains a valuable tool for investigating glutamate modulation. Future research could logically focus on genetically-defined patient populations where glutamate excitotoxicity is a primary disease driver or on the use of the drug in the very earliest, preclinical stages of diseases like AD, where it may have a greater chance of modifying the disease course. The ongoing exploration in oncology also remains a potential, albeit early-stage, avenue for future development.

Works cited

1. Troriluzole (also known as Trigriluzole, BHV-4157, and FC-4157) - Alzheimer's Drug Discovery Foundation, accessed September 1, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Troriluzole-Cognitive-Vitality-For-Researchers.pdf
2. Troriluzole (BHV-4157) | Glutamate Modulator - MedchemExpress.com, accessed September 1, 2025, https://www.medchemexpress.com/troriluzole.html
3. Troriluzole inhibits methamphetamine place preference in rats and ..., accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9850846/
4. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects (P4-4.012) - Neurology.org, accessed September 1, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000205210
5. DRUG: Troriluzole (BHV4157) STUDY NUMBER(S) - ClinicalTrials.gov, accessed September 1, 2025, https://cdn.clinicaltrials.gov/large-docs/41/NCT03829241/Prot_000.pdf
6. Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders (P4-4.013) - Neurology.org, accessed September 1, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000206182
7. ir.biohaven.com, accessed September 1, 2025, https://ir.biohaven.com/news-releases/news-release-details/fda-extends-pdufa-date-biohavens-troriluzole-nda-rare-disease#:~:text=The%20primary%20mode%20of%20action,clearing%20glutamate%20from%20the%20synapse.
8. FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia, accessed September 1, 2025, https://ir.biohaven.com/news-releases/news-release-details/fda-extends-pdufa-date-biohavens-troriluzole-nda-rare-disease/
9. Two Randomized, Double-Blind, Placebo-Controlled Trials of Troriluzole, A Novel Glutamate Modulating Agent, in Obsessive-Compulsive Disorder - Biohaven, accessed September 1, 2025, https://www.biohaven.com/wp-content/uploads/ASCP-2024-poster-troriluzole-OCD.pdf
10. Troriluzole dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed September 1, 2025, https://reference.medscape.com/drug/troriluzole-4000427
11. Troriluzole - Wikipedia, accessed September 1, 2025, https://en.wikipedia.org/wiki/Troriluzole
12. Glioblastoma Recruiting Phase 2 / 3 Trials for Troriluzole (DB15079) | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/indications/DBCOND0002893/clinical_trials/DB15079?phase=2%2C3&status=recruiting
13. Troriluzole Active Not Recruiting Phase 2 Trials for Obsessive Compulsive Disorder (OCD) Treatment - DrugBank, accessed September 1, 2025, https://go.drugbank.com/drugs/DB15079/clinical_trials?conditions=DBCOND0033099&phase=2&purpose=treatment&status=active_not_recruiting
14. Phase 2/3 Study of Troriluzole Shows No Statistically Significant Effects on Alzheimer Disease - - PracticalNeurology, accessed September 1, 2025, https://practicalneurology.com/news/phase-23-study-of-troriluzole-shows-no-statistically-significant-effects-on-alzheimer-disease/2469478/
15. Biohaven trashes troriluzole in OCD after asset bungles phase 3 trial - Fierce Biotech, accessed September 1, 2025, https://www.fiercebiotech.com/biotech/biohaven-trashes-troriluzole-ocd-after-asset-bungles-phase-3-trial
16. Phase 3 Clinical Trial Update of Troriluzole for Spinocerebellar Ataxia - - PracticalNeurology, accessed September 1, 2025, https://practicalneurology.com/news/phase-3-clinical-trial-update-of-troriluzole-for-spinocerebellar-ataxia/2469917/
17. Troriluzole: What is it and is it FDA approved? - Drugs.com, accessed September 1, 2025, https://www.drugs.com/history/troriluzole.html
18. Potential Spinocerebellar Ataxia Therapy Granted Priority Review and Is Available Through an Expanded Access Protocol - - PracticalNeurology, accessed September 1, 2025, https://practicalneurology.com/news/potential-spinocerebellar-ataxia-therapy-granted-priority-review-and-is-available-through-an-expanded-access-protocol/2473791/
19. Population Pharmacokinetic Modeling of Riluzole After Administration of a Next Generation Prodrug Troriluzole (S3.007) - Neurology.org, accessed September 1, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000205212
20. en.wikipedia.org, accessed September 1, 2025, https://en.wikipedia.org/wiki/Troriluzole#:~:text=While%20riluzole%20is%20typically%20taken,food%20along%20with%20greater%20bioavailability.
21. Dazluma | European Medicines Agency (EMA), accessed September 1, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/dazluma
22. Biohaven withdraws Troriluzole application to EMA for Spinocerebellar ataxias, accessed September 1, 2025, https://www.ataxia.org.uk/research-news/biohaven-withdraws-troriluzole-application-to-ema-for-spinocerebellar-ataxias/
23. Troriluzole | C15H16F3N5O4S | CID 121488186 - PubChem, accessed September 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Troriluzole
24. TRORILUZOLE - precisionFDA, accessed September 1, 2025, https://precision.fda.gov/ginas/app/ui/substances/e259e561-ef8e-4d56-9bba-870b5c0553ba
25. troriluzole | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 1, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=11375
26. troriluzole | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 1, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11375
27. 1926203-09-9 | Troriluzole - ChemScene, accessed September 1, 2025, https://www.chemscene.com/product/1926203-09-9.html
28. Troriluzole - CAS:1926203-09-9 - ATK CHEMICAL COMPANY, accessed September 1, 2025, http://www.atkchemical.com/product/16379.html
29. Troriluzole|Cas# 1926203-09-9 - GlpBio, accessed September 1, 2025, https://www.glpbio.com/troriluzole.html
30. Troriluzole hydrochloride | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/salts/DBSALT003366
31. Troriluzole hydrochloride - Orphanet, accessed September 1, 2025, https://www.orpha.net/en/drug/substance/628292?name=&mode=pat®ion=&status=all
32. Troriluzole hydrochloride (BHV-4157 hydrochloride) | Glutamate Modulator, accessed September 1, 2025, https://www.medchemexpress.com/troriluzole-hydrochloride.html
33. Compound: TRORILUZOLE (CHEMBL4297586) - ChEMBL - EMBL-EBI, accessed September 1, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL4297586
34. Troriluzole (also known as Trigriluzole, BHV-4157, and FC-4157) - Alzheimer's Drug Discovery Foundation, accessed September 1, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Troriluzole_UPDATE_1.pdf
35. TRORILUZOLE - Inxight Drugs, accessed September 1, 2025, https://drugs.ncats.io/drug/S7H48S6K7H
36. Riluzole: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/drugs/DB00740
37. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of Troriluzole in Healthy Subjects - Biohaven, accessed September 1, 2025, https://www.biohaven.com/wp-content/uploads/TRO-Pos-AAN24-SAD_MAD_FINAL4-12-24.pdf
38. Troriluzole Exhibits Favorable Hepatic Safety Profile ... - Biohaven, accessed September 1, 2025, https://www.biohaven.com/wp-content/uploads/BioH-TRO-HepaticSafety-POS-AAN-Final_4-12-24.pdf
39. Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder, accessed September 1, 2025, https://www.prnewswire.com/news-releases/biohaven-begins-pivotal-phase-3-trial-of-troriluzole-in-obsessive-compulsive-disorder-301199932.html
40. Upstate is part of national trial evaluating drug to slow Alzheimer's disease, accessed September 1, 2025, https://www.upstate.edu/news/articles/2019/2019-09-12-alzheimer.php
41. The pharmacology and mechanism of action of riluzole - Neurology.org, accessed September 1, 2025, https://www.neurology.org/doi/10.1212/WNL.47.6_Suppl_4.233S
42. The pharmacology and mechanism of action of riluzole - PubMed, accessed September 1, 2025, https://pubmed.ncbi.nlm.nih.gov/8959995/
43. Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia, accessed September 1, 2025, https://ir.biohaven.com/news-releases/news-release-details/biohaven-announces-fda-acceptance-and-priority-review/
44. Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA), accessed September 1, 2025, https://ir.biohaven.com/news-releases/news-release-details/biohaven-achieves-positive-topline-results-pivotal-study/
45. Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) - PR Newswire, accessed September 1, 2025, https://www.prnewswire.com/news-releases/biohaven-achieves-positive-topline-results-in-pivotal-study-of-troriluzole-in-spinocerebellar-ataxia-sca-302255056.html
46. Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - FirstWord Pharma, accessed September 1, 2025, https://firstwordpharma.com/story/5934419
47. www.neurology.org, accessed September 1, 2025, https://www.neurology.org/doi/10.1212/WNL.47.6_Suppl_4.233S#:~:text=Riluzole%20is%20a%20neuroprotective%20drug,from%20corticostriatal%20neurons%20in%20vivo.
48. The pharmacology and mechanism of action of riluzole - Neurology.org, accessed September 1, 2025, https://www.neurology.org/doi/pdfdirect/10.1212/WNL.47.6_Suppl_4.233S
49. Troriluzole for spinocerebellar ataxia | NIHR Innovation Observatory - Health Technology Briefing March 2024, accessed September 1, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2024/03/13450-Troriluzole-for-Spinocerebellar-Ataxia-V1.0-MAR2024-NON-CONF.pdf
50. Definition of trigriluzole - NCI Drug Dictionary, accessed September 1, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/troriluzole
51. Riluzole - Wikipedia, accessed September 1, 2025, https://en.wikipedia.org/wiki/Riluzole
52. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors - PMC - PubMed Central, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9250196/
53. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors - PubMed, accessed September 1, 2025, https://pubmed.ncbi.nlm.nih.gov/35780243/
54. Troriluzole for the Treatment of Recurrent IDH Wild Type Glioblastoma - NCI, accessed September 1, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09577
55. No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of Troriluzole - Biohaven, accessed September 1, 2025, https://www.biohaven.com/wp-content/uploads/TRO-Pos-AAN24-HepaticPK_FINAL-4-12-24.pdf
56. Spinocerebellar Ataxia - StatPearls - NCBI Bookshelf, accessed September 1, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557816/
57. Spinocerebellar Ataxia - Symptoms, Causes, Treatment | NORD, accessed September 1, 2025, https://rarediseases.org/rare-diseases/spinocerebellar-ataxia/
58. Therapeutic Strategies for Spinocerebellar Ataxia Type 1 - MDPI, accessed September 1, 2025, https://www.mdpi.com/2218-273X/13/5/788
59. Troriluzole Shows Promise in Spinocerebellar Ataxia Type 3 ..., accessed September 1, 2025, https://www.neurologylive.com/view/troriluzole-shows-promise-spinocerebellar-ataxia-type-3-subgroup-despite-failing-achieve-primary-end-point
60. Troriluzole Shows Promise in Spinocerebellar Ataxia Type 3 Subgroup Despite Failing to Achieve Primary End Point - NeurologyLive, accessed September 1, 2025, https://www.neurologylive.com/view/troriluzole-shows-promise-spinocerebellar-ataxia-type-3-subgroup-despite-failing-achieve-primary-end-point?page=1
61. Phase II/III trial of troriluzole in spinocerebellar ataxia - VJNeurology, accessed September 1, 2025, https://www.vjneurology.com/video/ezyq-w9upb0-phase-iiiii-trial-of-troriluzole-in-spinocerebellar-ataxia/
62. Troriluzole in Adult Participants With Spinocerebellar Ataxia - UCSF Clinical Trials, accessed September 1, 2025, https://clinicaltrials.ucsf.edu/trial/NCT03701399
63. Trial of BHV-4157 (Troriluzole) in Adult Subjects with Spinocerebellar Ataxia, accessed September 1, 2025, https://memory.ucsf.edu/research-trials/clinical-trials/bhv-4157
64. Troriluzole NDA PDUFA Date Extended to Q4 2025 - Medthority, accessed September 1, 2025, https://www.medthority.com/news/2025/5/fda-postpones-pdufa-date-to-q4-2025-for--troriluzole-nda--for-the-treatment-of-spinocerebellar-ataxia.--biohaven
65. Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia (S35.009) - Neurology.org, accessed September 1, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000205167
66. Riluzole and its prodrugs for the treatment of Alzheimer's disease - PMC, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10318568/
67. T2 Protect AD: Troriluzole Trial (T2) for Alzheimer's | Clinical Research Studies Listing, accessed September 1, 2025, https://research-studies.allinforhealth.info/us/en/listing/1471/t2-protect-ad-troriluzole/
68. Study Results | Study of BHV-4157 in Alzheimer's Disease | ClinicalTrials.gov, accessed September 1, 2025, https://clinicaltrials.gov/study/NCT03605667?intr=BHV-4157&rank=2&tab=results
69. Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled - BioSpace, accessed September 1, 2025, https://www.biospace.com/biohaven-provides-update-on-phase-2-3-alzheimer-s-disease-clinical-trial-over-400-patients-enrolled
70. Troriluzole for Obsessive-Compulsive Disorder · Info for Participants - Clinical Trials, accessed September 1, 2025, https://www.withpower.com/trial/phase-2-and-3-obsessive-compulsive-disorder-11-2017-49dc1
71. Treatment - Obsessive compulsive disorder (OCD) - NHS, accessed September 1, 2025, https://www.nhs.uk/mental-health/conditions/obsessive-compulsive-disorder-ocd/treatment/
72. Therapies for obsessive-compulsive disorder: Current state of the art and perspectives for approaching treatment-resistant patients - PMC, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9978117/
73. Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder, accessed September 1, 2025, https://www.yalemedicine.org/clinical-trials/a-randomized-double-blind-placebo-controlled-trial-of-adjunctive-troriluzole-in-ocd-1
74. Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder - UCSD Clinical Trials, accessed September 1, 2025, https://clinicaltrials.ucsd.edu/trial/NCT03299166
75. Biohaven Announces Obsessive-Compulsive Disorder (OCD) Proof Of Concept Phase 2/3 Study Results And Program Update - PR Newswire, accessed September 1, 2025, https://www.prnewswire.com/news-releases/biohaven-announces-obsessive-compulsive-disorder-ocd-proof-of-concept-phase-23-study-results-and-program-update-301082586.html
76. Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive ..., accessed September 1, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT04641143/efficacy-and-safety-study-of-adjunctive-troriluzole-in-obsessive-compulsive-disorder
77. Troriluzole for Spinocerebellar Ataxia · Info for Participants - Clinical Trials, accessed September 1, 2025, https://www.withpower.com/trial/phase-3-spinocerebellar-degenerations-2-2019-934e9
78. Biohaven gets a bump after FDA nixes adcom for troriluzole - FirstWord Pharma, accessed September 1, 2025, https://firstwordpharma.com/story/5991524
79. Pharma News - National Ataxia Foundation, accessed September 1, 2025, https://www.ataxia.org/pharmanews/
80. Troriluzole - Ataxia UK, accessed September 1, 2025, https://www.ataxia.org.uk/tag/troriluzole/
81. Biohaven (BHVN) Withdraws Troriluzole Application in Europe, Focus Shifts to U.S. Approval | BHVN Stock News - GuruFocus, accessed September 1, 2025, https://www.gurufocus.com/news/2805333/biohaven-bhvn-withdraws-troriluzole-application-in-europe-focus-shifts-to-us-approval--bhvn-stock-news
82. Biohaven Withdraws EU Application for Troriluzole in Spinocerebellar Ataxia, RBC Remains Optimistic - MedPath, accessed September 1, 2025, https://trial.medpath.com/news/394e52a71511a975/biohaven-withdraws-eu-application-for-troriluzole-in-spinocerebellar-ataxia-rbc-remains-optimistic